The user experienced hair loss since 2019 and tried finasteride, dutasteride, RU58841, and ketoconazole shampoo without success. A scalp biopsy showed scarring and inflammation from folliculitis, indicating chronic inflammation was affecting treatment effectiveness.
A user has been experiencing hair loss for 4 years, with treatments like minoxidil, finasteride, and various supplements proving ineffective. They were diagnosed with fibrosing alopecia in a pattern distribution, a condition that may require a combination of anti-inflammatory and hair growth treatments.
A 24-year-old male experienced side effects like low libido and ED after starting finasteride post-hair transplant and is seeking alternatives to reduce scalp DHT. Suggestions include topical finasteride, Xpecia, DHT-reducing shampoos, and switching to dutasteride, with some users reporting fewer side effects with these alternatives.
Pelage is developing a topical hair follicle stem cell therapy, PP405, for non-scarring alopecias like androgenetic alopecia, with Phase III trials planned and a potential market launch by 2027. The treatment may not require continuous use after initial regrowth.
Scalp biopsies are crucial for diagnosing hair loss conditions like Diffuse Unpatterned Alopecia (DUPA) and retrograde hair loss, as treatments like finasteride and dutasteride may not be effective if other conditions are present. Combining PPAR-GAMMA agonists with retinoids could improve treatments for conditions like Lichen Planopilaris.
Follicum discovered that their drug FOL-005 increased hair count by 12 hairs per cm2 in patients with less than 255 hairs per cm2 and is planning a phase 2b trial. They are currently fundraising for the trial, and the drug may also be effective for women.
Longitudinal partial follicular unit transplantation involves extracting part of the donor follicular unit, allowing the donor area to be overharvested without noticeable hair loss. The conversation questions if this method is practiced in clinics or if it's theoretical, and whether it relates to hair cloning or multiplication.
IGFBP‐rP1 shows potential for treating androgenic alopecia by influencing hair cycle transitions. Increasing IGF-1 levels may have similar effects to Minoxidil and 5-AR inhibitors in reducing hair loss.
Bicalutamide and spironolactone are being compared for their effectiveness and safety in treating female pattern hair loss. The conversation seeks advice on which is better to use.
The user is considering using topical finasteride for thinning hair around the middle part, vertex, and crown, and is unsure if the whole scalp is thinning. Another user suggests oral finasteride is more effective than topical, and recommends consulting a dermatologist for proper treatment.
A 23-year-old is considering using a topical solution of Finjuve (finasteride and minoxidil) at a reduced dosage of 0.2/0.4mg to treat crown thinning while minimizing side effects. Applying 0.1-0.2 mL is suggested to lower systemic absorption and effectively reduce DHT on the scalp.
A peptide-based delivery system for finasteride shows promise in reducing systemic side effects while maintaining hair growth effectiveness. Combining this with other treatments like minoxidil and RU58841 could enhance results with lower systemic absorption.
The post discusses a user's six-year progress with finasteride and a Follicular Unit Transplant (FUT) for hair loss. The user shared before and after photos in reverse order, leading to confusion, but overall, the community responded positively to the user's hair regrowth.
The user is experiencing diffuse androgenic alopecia and is trying various treatments, including 5mg finasteride, loniten, and Formula 82D, which contains dutasteride, a steroid, and tretinoin. They report potential regrowth with Formula 82D, despite previous treatments being ineffective.
A user discusses a topical treatment combining Minoxidil, Betamethasone Valerate, Canrenone, Finasteride, and Dutasteride for hair loss. The treatment is RX-only and provided by a dermatologist.
The conversation discusses the potential benefits of creating a hydrophobic version of finasteride to reduce systemic side effects while maintaining scalp health. It compares this idea to fluridil, which is designed to be hydrophobic and has less systemic absorption.
The user experienced hair regrowth and improved hair density using oral finasteride and topical minoxidil, with microneedling as an additional treatment. They are considering a hair transplant for low-density areas but are uncertain due to existing follicles.
The user experienced significant hair regrowth in three months using a capsule containing minoxidil and finasteride. They reported no major side effects and plan to continue the treatment until their late 20s.
The conversation discusses the fluctuation of testosterone levels in men under 40 and the difference between serum DHT and scalp DHT. It also mentions that DHT levels are higher on Dutasteride than on Finasteride, which is unusual.
The conversation is about a female seeking advice on using bicalutamide for female pattern hair loss (FPHL) and considering switching from pumpkin seed oil pills to a stronger treatment. She is looking for dosage information to discuss with her dermatologist.
The conversation discusses a topical finasteride therapy with hydrocortisone butyrate, estrone base, and breviline. A user suggests oral finasteride as a superior option.
The user is experiencing breast tenderness and lumps after three weeks on 0.5 mg oral finasteride, a common side effect. They also report mild brain fog and fatigue but are less concerned about these symptoms.
After nearly four months on finasteride, a user noticed improved hair quality but developed nipple puffiness, suggesting early signs of gynecomastia. They considered switching to other treatments like CB-03-01 or RU58841 and contemplated consulting an endocrinologist about aromatase inhibitors.
Follicusan DP is discussed as a potential alternative to Minoxidil without side effects, but information is scarce. It is noted to be of German origin and details on its mechanism are limited.
The conversation discusses the cost and insurance coverage of a comprehensive hormone and DHT blood panel for hair loss, with a focus on finasteride treatment. The user seeks a cheaper alternative to a $700 panel recommended in a video.
Finasteride can cause pelvic or urethral discomfort for some users. Reducing the dose to 0.25 mg on Mondays, Wednesdays, and Fridays is being considered as a potential solution.
A user reported that Procerin, containing Saw Palmetto and Pumpkin seed oil, provided similar hair thickening results as finasteride but with milder side effects. They experienced reduced libido and watery ejaculations but are adjusting the dose to minimize these effects.
A user experienced puffy nipples and lumps from finasteride, leading to a dilemma between continuing treatment with potential surgery or accepting hair loss. They restarted finasteride at a lower dose with supplements but still face side effects and are seeking advice on whether to persist or stop.